A 58-year-old male with type 2 diabetes, hypertension, and a history of myocardial infarction has an A1c of 8.1% despite being on metformin. Which of the following medication classes, when added to his regimen, has been shown to reduce cardiovascular mortality in patients with established atherosclerotic cardiovascular disease?
-
A
Dipeptidyl peptidase-4 (DPP-4) inhibitors
-
B
Sulfonylureas
-
C
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors
-
D
Thiazolidinediones (TZDs)